Digital Imaging Biomarkers In ILD/IPF Clinical Trials

Featuring Anna Podolanczuk, MD

 

Description

IPF (idiopathic pulmonary fibrosis), the most common subtype of ILD (interstitial lung disease), affects about 100,000 people in the US and millions globally. In this conversation, we explore Dr. Podolanczuk’s research in subclinical interstitial lung disease markers, the connection between cardiovascular disease and pulmonary fibrosis, and her advice to therapy developers designing clinical trials.

Highlights

Dr. Podolanczuk talks about the predictive power of HAA% (High Attenuation Area) as a digital imaging biomarker.

“We found a strong association of HAA at baseline and visually identifiable ILAs 10 years later.“

Advice for Pharma companies designing ILD/IPF clinical trials:

“You have a lot of flexibility in earlier stage trials to collect as much information as possible…“

Watch the Full Webinar

Speaker Bio

Anna Podolanczuk, MD

Assistant Professor of Medicine, Weill Cornell Medical College, Cornell University

Dr. Podolanczuk is a nationally and internationally recognized expert in interstitial lung disease. She received her undergraduate degree in Neuroscience from Brown University. She earned her MD from NYU School of Medicine. She completed residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at Columbia University. She received additional training in advanced pulmonary diseases at Columbia University. She also earned a Masters of Science in Patient-Oriented Research from Columbia’s Mailman School of Public Health, with a focus on epidemiology and biostatistics.

Dr. Podolanczuk is an NIH-funded investigator studying novel risk factors for pulmonary fibrosis in humans. Her research program focuses on understanding early or subclinical interstitial lung disease, characterizing imaging and blood biomarkers of pulmonary fibrosis, the role of environmental exposures, and the connection between cardiovascular disease and pulmonary fibrosis. She is also a site investigator for several multi-center clinical trials of new therapies for pulmonary fibrosis.